1. Academic Validation
  2. Nanocarrier-based drug delivery systems for bone cancer therapy: a review

Nanocarrier-based drug delivery systems for bone cancer therapy: a review

  • Biomed Mater. 2021 May 14;16(4). doi: 10.1088/1748-605X/abf7d5.
S Ram Prasad 1 T S Sampath Kumar 2 A Jayakrishnan 1
Affiliations

Affiliations

  • 1 Rajiv Gandhi Centre for Biotechnology, Jagathy, Trivandrum 695 014 Kerala, India.
  • 2 Medical Materials Laboratory, Department of Metallurgical and Materials Engineering, Indian Institute of Technology Madras, Chennai 600 036 Tamil Nadu, India.
Abstract

Bone Cancer is a malignant tumor that originates in the bone and destroys the healthy bone tissues. Of the various types of bone tumors, osteosarcoma is the most commonly diagnosed primary bone malignancy. The standard treatment for primary malignant bone tumors comprises surgery, chemotherapy and radiotherapy. Owing to the lack of proven treatments, different forms of alternative therapeutic approaches have been examined in recent decades. Among the new therapeutic methodologies, nanotechnology-based Anticancer therapy has paved the way for new targeted strategies for bone Cancer treatment and bone regeneration. They include approaches such as the co-delivery of multiple drug cargoes, the enhancement of their biodistribution and transport properties, normalizing accumulation and the optimization of drug release profiles to overcome shortcomings of the existing therapy. This review examines the standard treatments for osteosarcoma, their lacunae, and the evolving therapeutic strategies based on nanocarrier-mediated combinational drug delivery systems, and future perspectives for osteosarcoma therapy.

Keywords

bone cancer; chemotherapy; combinational; nanocarriers; osteosarcoma.

Figures